<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104476</url>
  </required_header>
  <id_info>
    <org_study_id>18331A</org_study_id>
    <nct_id>NCT05104476</nct_id>
  </id_info>
  <brief_title>A Study of Lu AF82422 in Participants With Multiple System Atrophy</brief_title>
  <acronym>AMULET</acronym>
  <official_title>Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Lu AF82422 in Patients With Multiple System Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out the effect of Lu AF82422 on disease progression in participants with multiple&#xD;
      system atrophy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The participants will be randomized to Lu AF82422 or placebo (2:1).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Unified Multiple System Atrophy Rating Scale (UMSARS) Part I and Part II Total Score (UMSARS TS) at the End of Treatment (EOT)</measure>
    <time_frame>Baseline, EOT (Week 48 to 72)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the UMSARS Part I, Modified UMSARS Part I (mUMSARS) and UMSARS Part II Scores at the EOT</measure>
    <time_frame>Baseline, EOT (Week 48 to 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in UMSARS TS, UMSARS Part I, mUMSARS and UMSARS Part II Scores at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Schwab and England Activities of Daily Living (SE-ADL) Score at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Impression - Severity of Illness (PGI-S) Score at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Observer-Reported Global Impression - Severity of Illness (OGI-S) Score at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Composite Autonomic Symptom Score Select Change (COMPASS Select Change) Score at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in UMSARS Part IV Score at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Speech, Swallowing, Falls, and Walking, as Assessed by the UMSARS Part I Item Scores at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Frequency, Cause, and Consequence of Falls, as Assessed by the Fall Diary Periods at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Score at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Brain Volume, as Measured by Volumetric MRI (vMRI) at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Tissue Integrity, as Measured by Diffusion-Tensor Imaging (DTI) MRI at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neurofilament Light Chain (NfL) Concentrations at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lu AF82422 Plasma Concentration</measure>
    <time_frame>0 to Week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lu AF82422 Cerebrospinal Fluid (CSF) Concentrations</measure>
    <time_frame>Weeks 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lu AF82422 CSF/Plasma Concentration Ratio</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>Lu AF82422</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Lu AF82422 intravenous (IV) infusion every 4 weeks (Q4W) from Baseline for a minimum 48 weeks up to a maximum 72 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Lu AF82422 matching placebo IV infusion Q4W from Baseline for a minimum 48 weeks up to a maximum 72 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF82422</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Lu AF82422</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  The participant is diagnosed with possible or probable MSA of the multiple system&#xD;
             atrophy parkinsonian type (MSA-P) or multiple system atrophy cerebellar type (MSA-C)&#xD;
             sub-type at the Screening Visit.&#xD;
&#xD;
          -  The participant had onset of motor and/or autonomic (orthostatic or urinary) MSA&#xD;
             symptoms within 5 years prior to the Screening Visit in the judgement of the&#xD;
             investigator.&#xD;
&#xD;
          -  The participant has an UMSARS Part I score ≤16 (omitting question 11 on sexual&#xD;
             function) at the Screening Visit.&#xD;
&#xD;
          -  The participant has a cognitive performance evaluated by the Montreal Cognitive&#xD;
             Assessment (MoCA) with a score ≥22 at the Screening Visit.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  The participant has been treated with an anti-α-synuclein monoclonal antibody,&#xD;
             mesenchymal stem cells or an inhibitor of α-synuclein aggregation within the last 12&#xD;
             months.&#xD;
&#xD;
          -  The participant has any past or current treatment with an active vaccine targeting&#xD;
             α-synuclein.&#xD;
&#xD;
          -  The participant has 2 or more blood relatives with a history of MSA.&#xD;
&#xD;
          -  The participant has evidence (clinically or on MRI) and/or history of any clinically&#xD;
             significant disease or condition other than MSA (for example, serious neurological&#xD;
             disorder, other intracranial disease, or systemic disease).&#xD;
&#xD;
          -  The participant has a current diagnosis of movement disorders that could mimic MSA&#xD;
             (for example, Parkinson' disease, dementia with Lewy bodies, essential tremor,&#xD;
             progressive supranuclear palsy, spinocerebellar ataxia, spastic paraparesis,&#xD;
             corticobasal degeneration, or vascular, pharmacological, or post-encephalitic&#xD;
             parkinsonism), per investigator discretion.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>H. Lundbeck A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple System Atrophy</keyword>
  <keyword>Neurodegenerative Disorder</keyword>
  <keyword>Autonomic Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

